JP2014513136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513136A5 JP2014513136A5 JP2014509491A JP2014509491A JP2014513136A5 JP 2014513136 A5 JP2014513136 A5 JP 2014513136A5 JP 2014509491 A JP2014509491 A JP 2014509491A JP 2014509491 A JP2014509491 A JP 2014509491A JP 2014513136 A5 JP2014513136 A5 JP 2014513136A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formula
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000004058 mixed glioma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- -1 ukrain Substances 0.000 claims description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 0 *C1=CCC(OCc2ccc3nc(N*)[s]c3c2)=CC=N1 Chemical compound *C1=CCC(OCc2ccc3nc(N*)[s]c3c2)=CC=N1 0.000 description 8
- 238000012360 testing method Methods 0.000 description 2
- OJKXHONIYMURKZ-VEDKUMTNSA-N C/C=C(\C=C(\c1c[n](C)nc1)/N)/Oc1ccc2nc(NC[C@@H](CCCC3)[C@H]3O)[s]c2c1 Chemical compound C/C=C(\C=C(\c1c[n](C)nc1)/N)/Oc1ccc2nc(NC[C@@H](CCCC3)[C@H]3O)[s]c2c1 OJKXHONIYMURKZ-VEDKUMTNSA-N 0.000 description 1
- QHPUOUFNQKXOJA-UHFFFAOYSA-N CNC(C(C1)N=CC=C1Oc(cc1)cc2c1nc(NC(CCCC1)C1O)[s]2)=O Chemical compound CNC(C(C1)N=CC=C1Oc(cc1)cc2c1nc(NC(CCCC1)C1O)[s]2)=O QHPUOUFNQKXOJA-UHFFFAOYSA-N 0.000 description 1
- ADZBMFGQQWPHMJ-YOEHRIQHSA-N CNC(c1cc(Oc2ccc3nc(N[C@@H](CCCC4)[C@H]4O)[s]c3c2)ccn1)=O Chemical compound CNC(c1cc(Oc2ccc3nc(N[C@@H](CCCC4)[C@H]4O)[s]c3c2)ccn1)=O ADZBMFGQQWPHMJ-YOEHRIQHSA-N 0.000 description 1
- ADZBMFGQQWPHMJ-UHFFFAOYSA-N CNC(c1nccc(Oc2ccc3nc(NC(CCCC4)C4O)[s]c3c2)c1)=O Chemical compound CNC(c1nccc(Oc2ccc3nc(NC(CCCC4)C4O)[s]c3c2)c1)=O ADZBMFGQQWPHMJ-UHFFFAOYSA-N 0.000 description 1
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N CNC(c1nccc(Oc2ccc3nc(N[C@H](CCCC4)[C@@H]4O)[s]c3c2)c1)=O Chemical compound CNC(c1nccc(Oc2ccc3nc(N[C@H](CCCC4)[C@@H]4O)[s]c3c2)c1)=O ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 description 1
- NJUWXYYFKUUWGU-UHFFFAOYSA-N CNCc1nccc(Oc2ccc3nc(N)[s]c3c2)c1 Chemical compound CNCc1nccc(Oc2ccc3nc(N)[s]c3c2)c1 NJUWXYYFKUUWGU-UHFFFAOYSA-N 0.000 description 1
- AIXXITODYRLCRH-MSOLQXFVSA-N C[n]1ncc(-c2cc(Oc3ccc4nc(NC[C@H](CCCC5)[C@@H]5C=C)[s]c4c3)ccn2)c1 Chemical compound C[n]1ncc(-c2cc(Oc3ccc4nc(NC[C@H](CCCC5)[C@@H]5C=C)[s]c4c3)ccn2)c1 AIXXITODYRLCRH-MSOLQXFVSA-N 0.000 description 1
- FCCUUXVXNBHGAZ-YLJYHZDGSA-N C[n]1ncc(-c2nccc(Oc3ccc4nc(N[C@H](CCCC5)[C@@H]5O)[s]c4c3)c2)c1 Chemical compound C[n]1ncc(-c2nccc(Oc3ccc4nc(N[C@H](CCCC5)[C@@H]5O)[s]c4c3)c2)c1 FCCUUXVXNBHGAZ-YLJYHZDGSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482723P | 2011-05-05 | 2011-05-05 | |
| US61/482,723 | 2011-05-05 | ||
| US201261624861P | 2012-04-16 | 2012-04-16 | |
| US61/624,861 | 2012-04-16 | ||
| PCT/US2012/036589 WO2012151523A1 (en) | 2011-05-05 | 2012-05-04 | Csf-1r inhibitors for treatment of brain tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513136A JP2014513136A (ja) | 2014-05-29 |
| JP2014513136A5 true JP2014513136A5 (enExample) | 2015-06-25 |
| JP6046702B2 JP6046702B2 (ja) | 2016-12-21 |
Family
ID=46062775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509491A Active JP6046702B2 (ja) | 2011-05-05 | 2012-05-04 | 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20140065141A1 (enExample) |
| EP (1) | EP2704713B1 (enExample) |
| JP (1) | JP6046702B2 (enExample) |
| KR (1) | KR101938431B1 (enExample) |
| CN (1) | CN103501785B (enExample) |
| BR (1) | BR112013028095B1 (enExample) |
| CA (1) | CA2834696C (enExample) |
| CY (1) | CY1119642T1 (enExample) |
| DK (1) | DK2704713T3 (enExample) |
| EA (1) | EA023999B1 (enExample) |
| ES (1) | ES2622527T3 (enExample) |
| HR (1) | HRP20170593T1 (enExample) |
| HU (1) | HUE032754T2 (enExample) |
| LT (1) | LT2704713T (enExample) |
| MX (1) | MX347616B (enExample) |
| PL (1) | PL2704713T3 (enExample) |
| PT (1) | PT2704713T (enExample) |
| SI (1) | SI2704713T1 (enExample) |
| WO (1) | WO2012151523A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014147631A1 (en) * | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
| WO2016182988A1 (en) | 2015-05-08 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
| JP6851322B2 (ja) * | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| US11065332B2 (en) | 2015-11-04 | 2021-07-20 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| KR20190069459A (ko) | 2016-10-14 | 2019-06-19 | 노파르티스 아게 | Csf-1r의 억제제를 사용한 안 질환의 치료 방법 |
| CN109843880B (zh) * | 2016-10-14 | 2023-12-01 | 诺华股份有限公司 | 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型 |
| MA46716A (fr) | 2016-11-03 | 2019-09-11 | Juno Therapeutics Inc | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| EP3631468A1 (en) | 2017-06-02 | 2020-04-08 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| KR20210110811A (ko) | 2018-11-30 | 2021-09-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법 |
| CN110468210A (zh) * | 2019-09-12 | 2019-11-19 | 暨南大学 | Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用 |
| EP4070097A1 (en) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating b cell malignancies |
| JP2023542041A (ja) * | 2020-09-21 | 2023-10-04 | ハチソン メディファルマ リミテッド | ヘテロ芳香族化合物及びその使用 |
| CN115969979B (zh) * | 2022-12-30 | 2025-08-29 | 中国人民解放军陆军军医大学第一附属医院 | C620-0580在制备抗胶质瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100721656B1 (ko) | 2005-11-01 | 2007-05-23 | 주식회사 엘지화학 | 유기 전기 소자 |
| UY30282A1 (es) * | 2006-04-14 | 2007-11-30 | Astrazeneca Ab | Compuestos quimicos |
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법 |
| EP2016070B1 (en) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| AU2008254425A1 (en) * | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
-
2012
- 2012-05-04 SI SI201230916A patent/SI2704713T1/sl unknown
- 2012-05-04 MX MX2013012939A patent/MX347616B/es active IP Right Grant
- 2012-05-04 PL PL12720761T patent/PL2704713T3/pl unknown
- 2012-05-04 LT LTEP12720761.1T patent/LT2704713T/lt unknown
- 2012-05-04 HU HUE12720761A patent/HUE032754T2/en unknown
- 2012-05-04 CA CA2834696A patent/CA2834696C/en active Active
- 2012-05-04 BR BR112013028095-6A patent/BR112013028095B1/pt not_active IP Right Cessation
- 2012-05-04 KR KR1020137031960A patent/KR101938431B1/ko not_active Expired - Fee Related
- 2012-05-04 DK DK12720761.1T patent/DK2704713T3/en active
- 2012-05-04 WO PCT/US2012/036589 patent/WO2012151523A1/en not_active Ceased
- 2012-05-04 HR HRP20170593TT patent/HRP20170593T1/hr unknown
- 2012-05-04 US US14/114,878 patent/US20140065141A1/en not_active Abandoned
- 2012-05-04 ES ES12720761.1T patent/ES2622527T3/es active Active
- 2012-05-04 EA EA201391629A patent/EA023999B1/ru not_active IP Right Cessation
- 2012-05-04 JP JP2014509491A patent/JP6046702B2/ja active Active
- 2012-05-04 EP EP12720761.1A patent/EP2704713B1/en active Active
- 2012-05-04 CN CN201280021878.2A patent/CN103501785B/zh active Active
- 2012-05-04 PT PT127207611T patent/PT2704713T/pt unknown
-
2015
- 2015-06-29 US US14/754,152 patent/US20150306085A1/en not_active Abandoned
-
2017
- 2017-04-10 CY CY20171100426T patent/CY1119642T1/el unknown
-
2018
- 2018-06-04 US US15/996,945 patent/US10537561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2017121233A5 (enExample) | ||
| Chang et al. | Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro | |
| JP2018505169A5 (enExample) | ||
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| BR112013028095A2 (pt) | inibidores de csf-1r para o tratamento de tumores cerebrais | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| JP2013507415A5 (enExample) | ||
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| MX387845B (es) | Polímeros enlazados al proton para administracion oral. | |
| JP2015524807A5 (enExample) | ||
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| EA201100409A1 (ru) | Замещенные производные триазолопиридазина | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| JP2016529285A5 (enExample) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. |